Lab Tests Before Starting GLP-1 Medication: What Your Doctor Orders and Why

Before prescribing a GLP-1 medication, many physicians order baseline blood work. These labs aren't bureaucratic hurdles — they're clinical tools that help your provider assess your metabolic health, identify risks, and establish reference points for monitoring how your body responds to treatment.

Here's what gets tested, why it matters, and what your results actually tell your doctor.

HbA1c and Fasting Glucose

What they measure: HbA1c reflects your average blood sugar over the past 2–3 months. Fasting glucose captures your blood sugar after an overnight fast.

Why they matter for GLP-1 therapy: GLP-1 agonists were originally developed as diabetes medications. These tests determine whether you have undiagnosed type 2 diabetes or prediabetes — conditions that influence medication choice, dosing, and expected outcomes. Patients with elevated HbA1c often see dual benefits from GLP-1 therapy: weight loss and improved glycemic control.

• Normal HbA1c: below 5.7%
• Prediabetes: 5.7% – 6.4%
• Diabetes: 6.5% or higher

Comprehensive Metabolic Panel (CMP)

What it covers: Kidney function (BUN, creatinine, eGFR), liver enzymes (ALT, AST), electrolytes (sodium, potassium, calcium), and blood glucose.

Why it matters: Kidney function affects drug clearance — severe renal impairment may require dose modifications or contraindicate certain GLP-1 formulations. Liver enzymes establish a baseline to detect hepatotoxicity during treatment. Electrolyte imbalances can be exacerbated by the nausea and reduced appetite common in early GLP-1 therapy.

Lipid Panel

What it measures: Total cholesterol, LDL ("bad" cholesterol), HDL ("good" cholesterol), and triglycerides.

Why it matters: Dyslipidemia is one of the qualifying comorbidities for GLP-1 prescriptions at BMI 27–29.9. Beyond qualification, lipid levels provide a cardiovascular risk baseline. Clinical trials — notably the SELECT trial for semaglutide — demonstrated significant reductions in major adverse cardiovascular events, making lipid tracking particularly relevant for monitoring treatment benefits.

Thyroid Function (TSH)

What it measures: Thyroid-stimulating hormone, the primary screening marker for thyroid disorders.

Why it matters: GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. While human risk remains unconfirmed, screening for thyroid abnormalities — and documenting the absence of personal or family history of medullary thyroid carcinoma — is standard clinical practice before prescribing.

Undiagnosed hypothyroidism can also contribute to weight gain and fatigue, potentially confounding treatment expectations if left unaddressed.

Complete Blood Count (CBC)

What it measures: Red blood cells, white blood cells, hemoglobin, hematocrit, and platelets.

Why it matters: While not GLP-1-specific, a CBC screens for anemia, infection, and other systemic conditions that could affect treatment tolerability. Patients with significant anemia may experience amplified fatigue during the caloric reduction that accompanies GLP-1 therapy.

Additional Tests Your Doctor May Order

• Vitamin D and B12: Deficiencies are common in patients with obesity and can worsen with reduced food intake during GLP-1 treatment.
• Insulin levels and HOMA-IR: Measures of insulin resistance that help predict GLP-1 response.
• Pregnancy test: GLP-1 agonists are contraindicated during pregnancy. Standard screening for women of childbearing age.
• Lipase and amylase: Baseline pancreatic enzyme levels, given the association between GLP-1 therapy and pancreatitis risk.

Do All Providers Require Labs?

Requirements vary. Some telehealth platforms require recent labs (within 6–12 months) or order them through partner networks. Others prescribe based on health history alone for lower-risk patients, with labs ordered during follow-up. Neither approach is inherently wrong — the key is whether your provider has enough clinical information to prescribe safely.